Caisse DE Depot ET Placement DU Quebec Has $1.53 Million Position in Astera Labs, Inc. $ALAB

Key Points

• Caisse DE Depot ET Placement DU Quebec reduced its stake in Astera Labs by 33.3%, leaving it with 25,700 shares valued at $1.53 million after selling 12,835 shares in the first quarter.
• A number of hedge funds, including Vanguard and Bank of Nova Scotia, have significantly increased their holdings in Astera Labs, indicating heightened institutional interest in the stock.
• Astera Labs reported a 149.5% year-over-year revenue increase of $191.93 million for the most recent quarter, surpassing analyst expectations of $172.46 million.

Caisse DE Depot ET Placement DU Quebec lessened its holdings in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 33.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,700 shares of the company's stock after selling 12,835 shares during the period. Caisse DE Depot ET Placement DU Quebec's holdings in Astera Labs were worth $1,534,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. NewEdge Advisors LLC acquired a new stake in shares of Astera Labs in the 4th quarter valued at $63,000. Banque Transatlantique SA acquired a new stake in shares of Astera Labs in the 4th quarter valued at $86,000. Gen Wealth Partners Inc acquired a new stake in shares of Astera Labs in the 4th quarter valued at $105,000. Sound Income Strategies LLC lifted its stake in shares of Astera Labs by 34.7% in the 1st quarter. Sound Income Strategies LLC now owns 792 shares of the company's stock valued at $47,000 after purchasing an additional 204 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Astera Labs by 55.7% in the 1st quarter. GAMMA Investing LLC now owns 794 shares of the company's stock valued at $47,000 after purchasing an additional 284 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company's stock.

Insiders Place Their Bets

In related news, CFO Michael Truett Tate sold 18,861 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $3,461,182.11. Following the sale, the chief financial officer owned 259,512 shares of the company's stock, valued at $47,623,047.12. The trade was a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jitendra Mohan sold 91,441 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total transaction of $16,780,337.91. Following the completion of the sale, the chief executive officer directly owned 2,170,877 shares in the company, valued at approximately $398,377,638.27. The trade was a 4.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,728,116 shares of company stock valued at $239,272,181 over the last 90 days. Company insiders own 12.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ALAB shares. Evercore ISI lifted their target price on shares of Astera Labs from $104.00 to $215.00 and gave the stock an "outperform" rating in a report on Wednesday, August 6th. Morgan Stanley lifted their target price on shares of Astera Labs from $155.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday. Wall Street Zen upgraded shares of Astera Labs from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Susquehanna lifted their target price on shares of Astera Labs from $80.00 to $125.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Finally, Northland Securities downgraded shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 target price on the stock. in a report on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Astera Labs currently has a consensus rating of "Moderate Buy" and an average price target of $135.75.

Astera Labs Stock Performance

Shares of NASDAQ:ALAB traded down $6.95 on Friday, hitting $182.20. 3,744,678 shares of the company were exchanged, compared to its average volume of 5,673,605. The company's 50 day moving average price is $132.43 and its two-hundred day moving average price is $95.70. Astera Labs, Inc. has a one year low of $36.85 and a one year high of $199.47. The firm has a market capitalization of $30.29 billion, a price-to-earnings ratio of 343.77, a PEG ratio of 4.62 and a beta of 1.46.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The company had revenue of $191.93 million for the quarter, compared to the consensus estimate of $172.46 million. During the same quarter in the previous year, the firm posted $0.13 EPS. The business's revenue was up 149.5% compared to the same quarter last year. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Research analysts predict that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.